Products in Development

At INSYS, we're focused on developing and commercializing innovative drugs and novel drug delivery systems that improve the quality of patients' lives.

Using our proprietary spray technology and our capability to develop pharmaceutical cannabinoids, we work to address the clinical shortcomings of existing commercial products.

Our product pipeline is concentrated on developing medicines that directly address areas of unmet medical needs, including pediatric epilepsy, such as infantile spasms, genetic disorders, anaphylaxis, anorexia, agitation in Alzheimer's disease, opioid dependence, and reversal of opioid-induced respiratory depression.

hello
Drug Candidate Disease State Status
SYNDROS®
(dronabinol) oral solution
label expansion
(i) Anorexia in cancer patients

(ii) Agitation in Alzheimer’s disease
Cannabidiol (i) Childhood absence epilepsy

(ii) Infantile spasm

(iii) Prader-Willi Syndrome
Buprenorphine
sublingual spray
Moderate-to-severe acute pain
Naloxone
nasal spray
Opioid overdose
Epinephrine
nasal spray
Anaphylaxis reaction
Buprenorphine / Naloxone sublingual spray Opioid dependence
Rizatriptan
nasal spray
Migraine  
SUBSYS®
(fentanyl sublingual spray)
label expansion
(i) Post-operative pain

(ii) Pre-procedural pain

CANNABINOIDS

SPRAYS

Approved Products

As a premier provider and manufacturer of innovative drugs and novel drug delivery systems, we aim to set new standards with our progressive line of products.

 

Approved Products

As a premier provider and manufacturer of innovative drugs and novel drug delivery systems, we aim to set new standards with our progressive line of products.